Palbociclib Enhances Migration and Invasion of Cancer Cells via Senescence-Associated Secretory Phenotype-Related CCL5 in Non-Small-Cell Lung Cancer

Palbociclib is the first CDK4/6 inhibitor approved by FDA and has been studied in many types of cancer. However, some studies showed that it could induce epithelial-mesenchymal transition (EMT) of cancer cells. To test the effect of palbociclib on non-small-cell lung cancer (NSCLC) cells, we treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Pengzhou, Yang, Xin, Zhang, Yingying, Dong, Huiling, Liu, Xiangchen, Xu, Xiaoqin, Zhang, Xinri, Shi, Yiwei, Hou, Mingxia, Song, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175017/
https://www.ncbi.nlm.nih.gov/pubmed/37181790
http://dx.doi.org/10.1155/2022/2260625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175017/
https://www.ncbi.nlm.nih.gov/pubmed/37181790
http://dx.doi.org/10.1155/2022/2260625

Ejemplares similares